Genetron Holdings Limited (GTH)

Genetron Holdings Limited (GTH) — VMCI valuation read

The headline on Genetron Holdings Limited (GTH) is a 45/100 VMCI score, set against a Healthcare sector median of 50. That 5-point below-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value drag is in the data.

GTH insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** GTH trades at 21.0x earnings, 17% above the Healthcare median of 18.0x sets the value side. ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 1.2x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on GTH.

GTH rose 0.6% over the trailing 7 days, with a -16.2% read on a 30-day basis.